Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, ...
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...